Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVIT... von Ascierto, Paolo Antonio, Lipson, Evan J, Dummer, Reinhard, Larkin, James, Long, Georgina V, Sanborn, Rachel E, Chiarion-Sileni, Vanna, Dréno, Brigitte, Dalle, Stéphane, Schadendorf, Dirk, Callahan, Margaret K, Nyakas, Marta, Atkinson, Victoria, Gomez-Roca, Carlos Alberto, Yamazaki, Naoya, Tawbi, Hussein A, Sarkis, Naomey, Warad, Deepti, Dolfi, Sonia, Mitra, Priyam, Suryawanshi, Satyendra, Grob, Jean-Jacques

Volltext

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myelo... von Bal, Susan, Htut, Myo, Nadeem, Omar, Anderson, Larry D., Koçoğlu, Hakan, Gregory, Tara, Rossi, Adriana C, Martin, Tom, Egan, Daniel N., Costa, Luciano, Hu, Hongxiang, Chen, Yanping, Li, Shaoyi, Kelly, Lisa M., Sarkis, Naomey, Ziyad, Safiyyah, Kao, Wei-Ming, Kaeding, Allison June, Burgess, Michael R., Berdeja, Jésus G

Volltext

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVIT... von Ascierto, Paolo Antonio, Lipson, Evan J, Dummer, Reinhard, Larkin, James, Long, Georgina V, Sanborn, Rachel E, Chiarion-Sileni, Vanna, Dréno, Brigitte, Dalle, Stéphane, Schadendorf, Dirk, Callahan, Margaret K, Nyakas, Marta, Atkinson, Victoria, Gomez-Roca, Carlos Alberto, Yamazaki, Naoya, Tawbi, Hussein A, Sarkis, Naomey, Warad, Deepti, Dolfi, Sonia, Mitra, Priyam, Suryawanshi, Satyendra, Grob, Jean-Jacques

Volltext